Astellas Pharma, Inc. is currently ahead in the non-hormonal menopausal relief race but Bayer AG is coming up on the rails after reporting positive results from two late-stage trials for elinzanetant.
Bayer Hot On The Trail Of Astellas As Menopause Drug Flies In Phase III
Astellas’s fezolinetant is already on the market but Bayer is confident its non-hormonal menopause drug elinzanetant will be able to catch up on the back of demonstrating significant reductions in the frequency and severity of hot flashes in a couple of Phase III trials.
More from Women's Health
• By
Deal Snapshot: Cosette will acquire struggling Mayne Pharma for about $430m, thereby augmenting its women’s health and dermatology portfolio and enhancing commercial capabilities.
• By
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
• By
Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.
• By
Interim results from an international Phase II study with its prolactin inhibiting antibody have boosted HopeMed’s confidence in its first-line potential in the chronic disorder, the Chinese venture's CEO tells Scrip.
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.